SPRO - Spero Therapeutics Inc Stock Price, Fair Value and News

1.46USD+0.03 (+2.10%)Market Closed

Market Summary

USD1.46+0.03

Market Closed

2.10%

SPRO Stock Price

View Fullscreen

SPRO RSI Chart

SPRO Valuation

Market Cap

78.6M

Price/Earnings (Trailing)

3.45

Price/Sales (Trailing)

0.76

Price/Free Cashflow

-2.38

SPRO Price/Sales (Trailing)

SPRO Profitability

Return on Equity

21.34%

Return on Assets

12.5%

Free Cashflow Yield

-41.95%

SPRO Fundamentals

SPRO Revenue

Revenue (TTM)

103.8M

Rev. Growth (Yr)

54.98%

Rev. Growth (Qtr)

188.63%

SPRO Earnings

Earnings (TTM)

22.8M

Earnings Growth (Yr)

91.22%

Earnings Growth (Qtr)

1.7K%

Breaking Down SPRO Revenue

Last 7 days

4.3%

Last 30 days

-16.6%

Last 90 days

-7.0%

Trailing 12 Months

-18.0%

How does SPRO drawdown profile look like?

SPRO Financial Health

Current Ratio

3.53

SPRO Investor Care

Shares Dilution (1Y)

2.47%

Diluted EPS (TTM)

0.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	53.5M	54.2M	77.7M	103.8M
2022	13.0M	9.9M	8.8M	53.5M
2021	14.9M	18.4M	17.4M	18.3M
2020	12.1M	11.7M	11.1M	9.3M
2019	10.5M	12.2M	16.2M	18.1M
2018	3.0M	3.2M	3.3M	4.0M
2017	663.7K	992.3K	1.3M	2.0M
2016	0	0	0	335.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Spero Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 05, 2024	shukla sath	sold	-65,384	1.45	-45,093	ceo and president
Feb 02, 2024	shukla sath	sold	-42,334	1.37	-30,901	ceo and president
Feb 02, 2024	joseph tamara l	sold	-42,341	1.37	-30,906	chief legal officer
Feb 02, 2024	hamed kamal	sold	-38,462	1.37	-28,075	chief medical officer
Feb 02, 2024	mahadevia ankit	sold	-87,399	1.37	-63,795	-
Feb 02, 2024	keutzer timothy	sold	-42,120	1.36	-30,971	chief operating officer
Feb 01, 2024	hamed kamal	acquired	-	-	239,731	chief medical officer
Feb 01, 2024	rajavelu esther	acquired	-	-	119,866	see remarks
Feb 01, 2024	joseph tamara l	acquired	-	-	239,731	chief legal officer
Feb 01, 2024	keutzer timothy	acquired	-	-	239,731	chief operating officer

Which funds bought or sold SPRO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	unchanged	-	150	1,032	-%
Apr 19, 2024	BOURGEON CAPITAL MANAGEMENT LLC	sold off	-100	-22,197	-	-%
Apr 15, 2024	PFS Partners, LLC	unchanged	-	12.00	86.00	-%
Apr 12, 2024	DLK Investment Management, LLC	unchanged	-	7,839	53,931	0.02%
Mar 11, 2024	VANGUARD GROUP INC	added	5.53	531,632	2,416,320	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	sold off	-100	-245	-	-%
Feb 14, 2024	Royal Bank of Canada	added	5.00	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	47,442	47,442	-%
Feb 14, 2024	AWM Investment Company, Inc.	unchanged	-	86,684	490,098	0.06%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	35,048	198,156	-%

Are Funds Buying or Selling SPRO?

Are funds buying SPRO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SPRO

No. of Funds

Unveiling Spero Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	anson funds management lp	8.1%	4,297,599	SC 13G
Feb 14, 2023	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2023	aquilo capital management, llc	0%	0	SC 13G/A
Jan 20, 2023	gsk plc	17.75%	9,190,606	SC 13D/A
Nov 14, 2022	gsk plc	19.99%	9,190,606	SC 13D/A
Oct 03, 2022	aquilo capital management, llc	3.6%	1,242,965	SC 13G/A
Jul 08, 2022	blackrock inc.	2.1%	690,753	SC 13G
Mar 09, 2022	aquilo capital management, llc	5.1%	1,642,655	SC 13G/A
Feb 14, 2022	aquilo capital management, llc	10.5%	3,378,881	SC 13G/A
Feb 14, 2022	biotechnology value fund l p	6.4%	2,169,102	SC 13G/A

Recent SEC filings of Spero Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	ARS	ARS
Apr 16, 2024	DEF 14A	DEF 14A
Apr 16, 2024	DEFA14A	DEFA14A
Mar 29, 2024	8-K	Current Report
Mar 22, 2024	EFFECT	EFFECT
Mar 20, 2024	CORRESP	CORRESP
Mar 20, 2024	UPLOAD	UPLOAD
Mar 15, 2024	S-3	S-3
Mar 15, 2024	S-8	Employee Benefits Plan
Mar 13, 2024	10-K	Annual Report

Peers (Alternatives to Spero Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Spero Therapeutics Inc News

Latest updates

Spero Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	188.6%	73,522,500	25,473,000	2,716,000	2,069,000	47,441,000	2,006,000	1,993,000	2,069,000	2,744,000	3,064,000	5,148,000	7,300,000	1,907,000	3,995,000	1,727,000	1,701,000	3,630,000	4,643,000	2,156,000	7,718,000	1,692,000
Operating Expenses	-16.1%	22,990,500	27,407,000	15,606,000	16,296,000	21,517,000	13,840,000	28,073,000	32,276,000	30,246,000	25,588,000	23,690,000	26,703,000	20,703,000	23,015,000	20,203,000	24,522,000	29,513,000	22,628,000	15,808,000	13,414,000	12,776,000
S&GA Expenses	12.7%	6,433,000	5,708,000	6,096,000	7,317,000	6,495,000	6,632,000	8,051,000	15,305,000	13,021,000	11,152,000	9,229,000	8,299,000	7,498,000	5,309,000	4,547,000	4,086,000	3,785,000	4,133,000	3,782,000	3,888,000	3,649,000
R&D Expenses	1.0%	16,557,500	16,393,000	9,510,000	8,979,000	15,089,000	7,360,000	8,173,000	16,971,000	17,225,000	14,436,000	14,461,000	18,404,000	13,205,000	17,706,000	15,656,000	20,436,000	25,728,000	18,495,000	12,026,000	9,526,000	9,127,000
EBITDA Margin	-	-	-	-	-	-	-	-9.02	-6.84	-4.88	-	-	-5.19	-8.30	-5.47	-5.14	-4.96	-3.31	-2.51	-3.36	-3.91	-
Income Taxes	-82.4%	387,000	2,200,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-	-	-	-	-	-	-	-9.09	-6.89	-4.92	-	-	-5.24	-8.39	-5.51	-5.21	-5.02	-3.36	-2.57	-3.41	-3.96	-
Net Income	1697.2%	51,191,000	-3,205,000	-11,914,000	-13,266,000	26,771,000	-11,675,000	-28,682,000	-32,829,000	-29,240,000	-22,521,000	-18,572,000	-19,423,000	-18,585,000	-18,936,000	-17,501,000	-23,258,000	-24,986,000	-17,717,000	-13,150,000	-5,072,000	-10,599,000
Net Income Margin	1157.9%	0.22	-0.02	-0.19	-0.50	-0.87	-11.62	-11.48	-7.92	-4.92	-4.54	-4.12	-4.99	-8.39	-	-	-	-	-	-	-	-
Free Cashflow	-209.9%	-17,493,000	15,915,000	-18,564,000	-12,853,000	44,482,000	-957,000	-23,033,000	-28,223,000	-27,349,000	-4,952,000	-16,579,000	-15,491,000	-16,395,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	70.3%	182	107	99.00	113	125	64.00	64.00	146	171	145	120	143	153	157	98.00	110	106	113	122	125	129
Current Assets	28.4%	131	102	88.00	102	114	53.00	52.00	133	158	132	106	129	139	143	85.00	98.00	95.00	104	113	116	124
Cash Equivalents	-18.6%	76.00	94.00	78.00	96.00	109	50.00	45.00	72.00	113	113	72.00	77.00	85.00	125	65.00	64.00	30.00	46.00	71.00	49.00	34.00
Net PPE	-95.1%	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00
Liabilities	41.4%	75.00	53.00	44.00	48.00	49.00	32.00	28.00	83.00	83.00	33.00	29.00	25.00	21.00	24.00	24.00	27.00	32.00	19.00	13.00	11.00	13.00
Current Liabilities	45.9%	37.00	25.00	17.00	23.00	22.00	16.00	14.00	69.00	19.00	17.00	13.00	18.00	14.00	18.00	19.00	23.00	27.00	15.00	8.00	7.00	12.00
Shareholder's Equity	99.0%	107	54.00	55.00	65.00	76.00	32.00	36.00	62.00	88.00	112	90.00	119	132	133	74.00	82.00	75.00	93.00	110	113	116
Retained Earnings	11.6%	-391	-442	-439	-427	-413	-440	-428	-400	-367	-338	-315	-297	-277	-259	-240	-222	-199	-174	-156	-143	-138
Additional Paid-In Capital	0.4%	498	496	494	492	490	473	465	463	456	450	406	416	410	392	314	305	274	267	266	257	254
Shares Outstanding	0.0%	53.00	53.00	53.00	53.00	52.00	36.00	33.00	33.00	32.00	30.00	30.00	29.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00
Float	-	-	-	76.00	-	22.00	-	-	-	-	-	326	-	-	-	256	-	-	-	151	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-209.9%	-17,493	15,915	-18,564	-12,853	44,482	-957	-23,033	-28,223	-27,349	-4,952	-16,567	-15,479	-16,383	-21,264	-24,896	-23,329	-17,367	-9,659	-12,070	-10,924	-13,509
Share Based Compensation	4.7%	1,997	1,908	1,857	2,170	2,497	2,106	1,317	3,203	2,928	2,330	2,163	2,009	1,365	1,199	1,214	1,110	929	981	933	933	769
Cashflow From Investing	-	-	-	-	-	-	-129	50,000	-16,064	-23,275	17,025	10,919	3,003	-39,740	3,949	18,485	27,776	-4,099	-15,887	24,845	24,671	7,287
Cashflow From Financing	-99.5%	1.00	220	-	-	14,179	6,131	-53,677	3,814	50,349	29,224	168	4,309	16,090	77,215	7,390	30,186	5,599	10.00	8,963	1,568	-178

SPRO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Grant revenue	$ 7,046	$ 4,930
Collaboration revenue - related party	95,802	46,076
Collaboration revenue	$ 933	$ 2,503
Type of Revenue [Extensible List]	License [Member]	License [Member]
Total revenues	$ 103,781	$ 53,509
Operating expenses:
Research and development	51,440	47,593
General and administrative	25,554	36,483
Impairment of assets	5,306	635
Restructuring	0	11,630
Total operating expenses	82,300	95,706
Income (loss) from operations	21,481	(42,197)
Other income (expense):
Interest income	3,937	1,106
Other income (expense), net	(14)	(55)
Interest expense related to the sale of future royalties	0	(2,605)
Loss on extinguishment of liability related to the sale of future royalties	0	(3,581)
Change in fair value of derivative liability	0	917
Total other income (expense), net	3,923	(4,218)
Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net, Total	25,404	(46,415)
Income tax expense	(2,598)	0
Net income (loss)	$ 22,806	$ (46,415)
Net loss per share attributable to common stockholders, basic	$ 0.43	$ (1.23)
Net loss per share attributable to common stockholders, diluted	$ 0.43	$ (1.23)
Basic weighted average common shares outstanding	52,703,467	37,585,075
Weighted Average Number of Shares Outstanding, Diluted	52,989,030	37,585,075
Comprehensive income (loss):
Net income (loss)	$ (22,806)	$ 46,415
Other comprehensive gain (loss):
Unrealized gain on marketable securities	0	2
Net unrealized gains (losses) on securities	0	2
Total comprehensive income (loss)	$ 22,806	$ (46,413)

SPRO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 76,333	$ 109,107
Collaboration receivable, current - related party	49,152	0
Other receivables	1,545	1,084
Prepaid expenses and other current assets	4,178	3,379
Total current assets	131,208	113,570
Property and equipment, net	2	368
Collaboration receivable, non-current - related party	46,590	0
Operating lease right-of-use assets	4,155	5,124
Other assets	435	5,740
Total assets	182,390	124,802
Current liabilities:
Accounts payable	1,378	617
Accrued expenses and other current liabilities	6,557	8,973
Operating lease liabilities	1,718	1,690
Income taxes payable	387	0
Deferred Revenue, Current	2,132	4,149
Deferred revenue, current - related party	24,981	6,220
Total current liabilities	37,153	21,649
Non-current operating lease liabilities	3,825	4,957
Deferred revenue, non-current	10,825	9,741
Deferred revenue, non-current - related party	23,606	12,425
Other long-term liabilities	87	96
Total liabilities	75,496	48,868
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2023 and 2022; 52,999,680 shares issued and outstanding as of December 31, 2023 and 52,456,195 shares issued and outstanding as of December 31, 2022	53	52
Additional paid-in capital	497,913	489,760
Accumulated deficit	(391,072)	(413,878)
Accumulated other comprehensive income (loss)	0	0
Total stockholders' equity	106,894	75,934
Total liabilities and stockholders' equity	$ 182,390	$ 124,802

About Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Satyavrat Shukla C.F.A.
WEBSITE	https://sperotherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	35

Spero Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Spero Therapeutics Inc? What does SPRO stand for in stocks?

SPRO is the stock ticker symbol of Spero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Spero Therapeutics Inc (SPRO)?

As of Fri Apr 26 2024, market cap of Spero Therapeutics Inc is 78.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SPRO stock?

You can check SPRO's fair value in chart for subscribers.

What is the fair value of SPRO stock?

You can check SPRO's fair value in chart for subscribers. The fair value of Spero Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Spero Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SPRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Spero Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SPRO is over valued or under valued. Whether Spero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Spero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SPRO.

What is Spero Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, SPRO's PE ratio (Price to Earnings) is 3.45 and Price to Sales (PS) ratio is 0.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SPRO PE ratio will change depending on the future growth rate expectations of investors.